Dexmedetomidine inhibits inflammation and angiogenesis and alleviates esophageal cancer progression through ITGA6/PI3K/AKT pathway: Dexmedetomidine inhibits esophageal cancer progression. Indian J Exp Biol [Internet]. 2026 Feb. 16 [cited 2026 May 13];64(01):15-32. Available from: https://or.niscpr.res.in/index.php/IJEB/article/view/22881